Lyell Immunopharma has begun dosing in a first-of-its-kind phase 3 head-to-head randomized trial in second-line large B-cell lymphoma, testing its dual-target CAR T ronde-cel against investigator’s choice of axi-cel or liso-cel. In parallel, the company’s single-arm pivotal PINACLE trial in third-line and later LBCL continues as the data backbone for a planned BLA, while its solid tumor program LYL273 in metastatic colorectal cancer has advanced dose escalation without dose-limiting toxicity. Lyell also closed a second $50 million tranche from a previously announced $100 million private placement tied to a pivotal trial milestone and ended 2025 with $247.2 million in cash and securities, extending runway into the second quarter of 2027 alongside a newly appointed chief financial and business officer.

This head-to-head design is a calculated escalation in a market where differentiation has relied on cross-trial comparisons and real-world data. If ronde-cel can deliver superior event-free survival with manageable toxicity in the second-line setting, payers will finally have comparative evidence to justify preferential coverage, and treatment centers could have a clinical narrative to displace entrenched options. The strategic question is whether comparative efficacy plus an outpatient-capable safety profile can overcome the incumbents’ manufacturing scale, installed base at accredited centers, and deep real-world outcomes datasets.

The stakes are immediate for patients, payers, and competitors. Patients with high-risk, primary refractory disease need deeper and more durable responses; by targeting CD19 or CD20 with an OR logic gate and enriching for CD62L-positive, stem-like T cells, ronde-cel is designed to blunt antigen escape and prolong durability. Payers have been signaling fatigue with me-too cell therapies; a randomized second-line readout against axi-cel or liso-cel is the evidentiary threshold that can unlock formulary differentiation and possibly steer site-of-care to outpatient, where Lyell’s dexamethasone-prophylaxis experience suggests lower rates of severe CRS and ICANS. For HCPs, a clearer toxicity profile that fits outpatient workflows changes staffing, referral, and monitoring patterns, but also raises new operational questions about bridging, washout, and clinic readiness if volumes shift outside the inpatient setting.

The move also aligns with broader currents in cell therapy. Next-generation CAR Ts are converging on dual-antigen recognition and T-cell fitness engineering to address relapse biology and extend durability. At the same time, the evidence bar is rising: payers and HTA bodies are rewarding randomized, head-to-head data over single-arm registrational studies, especially in earlier lines. Lyell’s internal manufacturing capacity and stated commercial readiness echo a vertical-integration trend among cell therapy players aiming to control vein-to-vein reliability and cost. Meanwhile, the push into solid tumors with LYL273—combining GCC targeting, CD19 CAR co-expression, and controlled cytokine release—signals renewed confidence that engineered T cells can function in hostile microenvironments, with early response and disease-control signals that will invite close Medical Affairs engagement to define eligibility, on-treatment management, and endpoints acceptable to payers.

For business development teams, the milestone-triggered financing and trimmed operating base show investors still back platform differentiation tied to near-term catalysts. For incumbents, the question is whether to counter with their own randomized expansions, price concessions, or service advantages such as faster turnaround and broader center access. The next 12–18 months will test if randomized superiority and outpatient-manageable safety can reset second-line LBCL treatment economics—and whether early solid tumor signals are robust enough to pull capital and clinical resources back toward CAR T beyond hematologic malignancies.

Source link: https://www.globenewswire.com/news-release/2026/03/12/3255090/0/en/Lyell-Immunopharma-Reports-Q4-and-Full-Year-2025-Business-and-Financial-Results.html

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.